Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
- Tools Icon Tools
- Search Site
E P Sampaio, E N Sarno, R Galilly, Z A Cohn, G Kaplan; Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.. J Exp Med 1 March 1991; 173 (3): 699–703. doi: https://doi.org/10.1084/jem.173.3.699
Download citation file: